The phase III study of the Covaxin, which initially spanned at 25 clinical sites across the country, inducted several more sites in the last week of December since many sites were unable to find the volunteers for the study. Dr. Dhananjay Lad, co-investigator of the trial at Redkar Hospital, Goa, told IANS that the trial was extended to around 30 clinical sites.